A U.S. judge has approved a legal settlement that requires Merck & Co.'s (MRK) drug research arm to inform the company's board of directors of delays in reporting clinical trial results.
The settlement ends part of the litigation that followed the 2008 release of results of the "Enhance" clinical trial of Merck's cholesterol drug Vytorin, which raised questions about its efficacy, nearly two years after the study was completed in 2006. The data caused Vytorin sales to decline.
Read more: http://www.foxbusiness.com/news/201...olster-clinical-data-reporting/#ixzz1nuYyP3F3
The settlement ends part of the litigation that followed the 2008 release of results of the "Enhance" clinical trial of Merck's cholesterol drug Vytorin, which raised questions about its efficacy, nearly two years after the study was completed in 2006. The data caused Vytorin sales to decline.
Read more: http://www.foxbusiness.com/news/201...olster-clinical-data-reporting/#ixzz1nuYyP3F3